Abstract
Objectives: To evaluate patient outcomes in borderline resectable and locally advanced pancreatic cancer treated with one of three approaches: 1) Total neoadjuvant therapy (TNT) comprised of chemotherapy followed by neoadjuvant stereotactic body radiation (SBRT) followed by pancreaticoduodenectomy. 2) Neoadjuvant Chemotherapy and Surgery (NeoC-S) comprised of chemotherapy followed by immediate pancreaticoduodenectomy. 3) Chemo-SBRT (NeoC-SBRT) comprised of neoadjuvant therapy followed by SBRT without surgery.
Methods: Between October 2011 and June 2015, 80 patients with borderline resectable nonmetastatic pancreatic adenocarcinoma underwent one of the above treatment approaches including 25 with TNT, 6 with NeoC-S and 49 with NeoC-SBRT. Clinical characteristics at diagnosis including performance status, CA 19-9, clinical stage, degree of vascular involvement and pathologic staging along with margin status were obtained. For patients who received SBRT, the majority of patients received 30 Gy in 3 fractions over 5 days via CyberKnife with fiducial guidance. Kaplan-Meier method with Log-Rank testing for significance was used to compare overall survival (OS), metastasis free survival and local recurrence.
Results: After a median follow-up of 13.3 months, median OS for the study group was 22.2 months. Patients in the NeoC-S group were younger (median age 57 yrs), had better performance status (83% ECOG 0) and were less likely to have major vessel involvement (50%). Conversely, NeoC-SBRT patients were older (median age 69.5 years), had worse performance status (37% ECOG 0), had a higher CA 19-9 (median 190) and were less likely to get FOLFIRINOX chemotherapy (53%). Patients who received TNT had a statistically significant longer median OS compared to NeoC-SBRT patients (36.5 mo. vs. 19.3 mo.; p=0.02) and a near significant improvement in survival compared to NeoC-S patients (median OS 36.5 mo vs. 22.2 months; p-value TNT vs. NeoC 0.17). There was no significant difference in OS between patients in the NeoC-S and NeoC-SBRT groups (p=0.98). Similarly, metastasis free survival (MFS) was improved with TNT (23.4 mo.) as compared to NeoC-SBRT (15.1 mo.; p=0.001) but not significantly different as compared to NeoC (21 mo.; p=0.42). There was no significant difference between MFS in the NeoC-S and NeoC-SBRT groups (p=0.37). 1-year rates of freedom from local failure were not statistically significant between treatment groups (95% TNT, 83%
